Category Archives: News

SOM BIOTECH AT BIO INTERNATIONAL CONVENTION 2015 (BOOTH #2301)

SOM Biotech will attend next Bio International Convention in Philadelphia, the world’s largest biotechnology gathering. It allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies. The BIO Convention will host thousands of organizations including the leading biotech …

4TH ANNUAL DRUG REPOSITIONING, REPURPOSING AND RESCUE CONFERENCE

Dr. Raúl Insa, SOM Biotech CEO, will be one of the speakers at the 4th Annual Drug Repositioning, Repurposing and Rescue Conference. This relevant event will be held in Chicago, IL, from May 27-28, 2015. During the event, the latest developments in the fields of drug repositioning, repurposing and rescue will highlighted. This conference continues to serve as …

DR. INSA AT THE 2ND SESSION OF LESSONS LEARNED 2015

Dr. Raúl Insa, SOM Biotech CEO, will participate in the 2nd Session of Lessons Learned 2015, exciting seminar where clinical development process will be discussed. This event is organized by CataloniaBio and will be held in the Scientific Park of Barcelona during April 21st 2015.  For further information visit CataloniaBio: Lessons Learned (in Catalan)

SOM BIOTECH AT BIO-EUROPE 2014 IN FRANKFURT

SOM Biotech will attend next BIO-Europe, Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry. This event will take place in Frankfurt from 3-5 November …

SOM BIOTECH OBTAINS THE APPROVAL FROM REGULATORY AUTHORITIES TO CARRY OUT THE PHASE IIA CLINICAL TRIAL FOR TTR AMYLOIDOSIS

SOM Biotech has just obtained the approval from the Ethics Committee of Hopital Vall d’Hebron and the Spanish Medicines Agency (AEMPS) to start the Phase IIa clinical trial of its compound SOM0226 indicated for transthyretin Amyloidosis. This trial will be jointly coordinated by SOM Biotech and Vall d’Hebron Research Institute (VHIR). The principal investigator of …